The Conversation (0)
Abattis Bioceuticals signed a letter of intent with dicentra for a suite of services to support Abattis’s current and future regulatory and compliance needs.
Abattis Bioceuticals (CSE:ATT; OTC:ATTBF) signed a letter of intent with dicentra for a suite of services to support Abattis’s current and future regulatory and compliance needs.
As quoted in the press release:
Pursuant to the LOI, Abattis and dicentra have agreed to negotiate in good faith the terms of a definitive agreement respecting the Partnership, which agreement will include representations, warranties and covenants typical for an arrangement of similar nature to the Partnership and will supersede the LOI.
With more than 1,000 clients served internationally, over 15,000 projects successfully completed and offices in Canada and the United States, dicentra is a leading consulting firm with 16 years of experience providing regulatory and compliance services.
“Bringing dicentra’s experience and expertise to Abattis will help us to secure world-class regulatory and compliance services for Abattis and our clients and partners”, stated Rob Abenante, President and CEO of Abattis.
